U.S. Food And Drug Administration Approves ONGLYZA? (saxagliptin) For The Treatment Of Type 2 Diabetes Mellitus In Adults

Podiatry Arena U.S. Food And Drug Administration Approves ONGLYZA? (saxagliptin) For The Treatment Of Type 2 Diabetes Mellitus In Adults

Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.

U.S. Food And Drug Administration Approves ONGLYZA? (saxagliptin) For The Treatment Of Type 2 Diabetes Mellitus In Adults

Submit Thread >

< Submit Thread

Thread Tools

Display Modes

1st August 2009, 03:30 AM

RSSFeedBot RSSFeedBot is offline

I, Robot

About:

Join Date: Jul 2008

Posts: 3,061

Join Date: Jul 2008

Marketplace reputation 0% (0)

CPD Points: 1

Thanks: 0

Thanked 5 Times in 5 Posts

U.S. Food And Drug Administration Approves ONGLYZA? (saxagliptin) For The Treatment Of Type 2 Diabetes Mellitus In Adults

Podiatry Arena members do not see these ads

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) approved ONGLYZA? (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor. ONGLYZA is indicated as an adjunct to diet and exercise to improve blood sugar (glycemic) control in adults for the treatment of type 2 diabetes mellitus.

More...

Sponsored Links

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts	vB code is On Smilies are On [IMG] code is On HTML code is On

Forum Jump

Translate This Page

Similar Threads

Thread	Thread Starter	Forum	Replies	Last Post
Update On FDA Advisory Committee Meeting On Liraglutide For The Treatment Of Type 2 Diabetes	RSSFeedBot	Latest Diabetes Medicine Research & News	0	9th April 2009 05:10 AM
Surveyed Experts Indicate That Byetta LAR And Victoza Have Advantages Over Actos In The Treatment Of Type 2 Diabetes	RSSFeedBot	Latest Diabetes Medicine Research & News	0	25th March 2009 06:10 AM
FDA Approves First Gout Drug For 40 Years	RSSFeedBot	Latest Rheumatology News	0	16th February 2009 07:40 AM
New Survey Uncovers Significant Food Economising Amongst Type 2 Diabetes Population. Is Global Credit Crunch To Blame?	RSSFeedBot	Latest Diabetes Medicine Research & News	0	3rd February 2009 09:10 AM
New paradigm proposed for treatment of type 2 diabetes	NewsBot	Diabetic Foot & Wound Management	1	24th July 2008 03:29 PM

New To Site?	Need Help?
Register to Participate View Forum Leaders Contact Us	Frequently Asked Questions Did you forget your password? Mark Forums Read

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.

All times are GMT -7. The time now is 05:16 PM.

User Name		Remember Me?
Password